Clinical Trial Detail

NCT ID NCT03836209
Title Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors PrECOG, LLC.
Indications

acute myeloid leukemia

Therapies

Cytarabine + Daunorubicin + Gilteritinib

Cytarabine + Daunorubicin + Midostaurin

Cytarabine

Midostaurin

Age Groups: senior adult

Additional content available in CKB BOOST